Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/8347Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Derdemezis, C. S. | en |
| dc.contributor.author | Filippatos, T. D. | en |
| dc.contributor.author | Voulgari, P. V. | en |
| dc.contributor.author | Tselepis, A. D. | en |
| dc.contributor.author | Drosos, A. A. | en |
| dc.contributor.author | Kiortsis, D. N. | en |
| dc.date.accessioned | 2015-11-24T16:40:59Z | - |
| dc.date.available | 2015-11-24T16:40:59Z | - |
| dc.identifier.issn | 0392-856X | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/8347 | - |
| dc.rights | Default Licence | - |
| dc.subject | ankylosing spondylitis | en |
| dc.subject | infliximab | en |
| dc.subject | tnf | en |
| dc.subject | leptin | en |
| dc.subject | adiponectin | en |
| dc.subject | rheumatoid-arthritis | en |
| dc.subject | adipose-tissue | en |
| dc.subject | disease-activity | en |
| dc.subject | plasma-levels | en |
| dc.subject | inflammation | en |
| dc.subject | adipokines | en |
| dc.subject | therapy | en |
| dc.subject | index | en |
| dc.subject | mediators | en |
| dc.subject | insulin | en |
| dc.title | Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | <Go to ISI>://000286918800012 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας | el |
| heal.publicationDate | 2010 | - |
| heal.abstract | Background. Adipose tissue-derived leptin and adiponectin control hunger, energy expenditure, insulin sensitivity, endothelial function, reproduction and immunity and are thought to play a role in autoimmune diseases. However, their role in ankylosing spondylitis (AS) is not clearly defined. Tumour necrosis factor TNF-alpha is a potential modulator of adipocytokines. The effect of long-term anti-TNF-alpha treatment on plasma levels of leptin and adiponectin has not been assessed so far. Objectives. To assess the effect of a 6-month anti-TNF-alpha treatment on serum leptin and adiponectin levels in AS patients. Methods. Thirty men with AS were included in the study. Thirty age- and weight-matched men served as controls. Clinical and biochemical parameters were assessed and serum levels of leptin and adiponectin were measured with enzyme immunoassay methods prior to and after the 6-month treatment with infliximab. Results. Mean age and disease duration of AS patients were 40.6+/-13.7 and 13.4+/-8.4 years, respectively. At baseline, AS patients exhibited significantly higher adiponectin (15.4+/-8.3 vs. 8.6+/-4.2 p<0.05), but no difference in leptin levels (7.2+/-2.9 vs. 8.9+/-6.4 ng/ml, p=NS). Adipocytokines did not correlate with any disease parameter. Body weight of the patients did not change significantly over the 6-month period. Serum levels of leptin and adiponectin did not change significantly otter the 6-month treatment. Conclusion. Adiponectin levels were significantly higher in AS patients compared with controls. Infliximab treatment did not change serum levels of leptin and adiponectin suggesting that the anti-TNF-alpha treatment may not modulate significantly their levels. | en |
| heal.journalName | Clin Exp Rheumatol | en |
| heal.journalType | peer reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
